TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03603574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWA through the needle
Description: In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWA through the catheter
Description: In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
Study: NCT04697108

Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder reproduction teste assisted by laser pointer
Description: In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
Study: NCT03769389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Birhi
Description: Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Birhi
Description: Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Birhi
Description: Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Khassab
Description: 34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Khassab
Description: 34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Khassab
Description: 34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 50g of pure glucose dissolved in 100ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 50g of pure glucose dissolved in 100ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 50g of pure glucose dissolved in 100ml of water
Study: NCT03619902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized monoclonal antibody
Study: NCT00542217

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG
Study: NCT01680146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRO+FAT

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PRO
Study: NCT00803296

Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT)

Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT)

Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT)

Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT)

Intervention type: OTHER
Intervention: Isoglycemic intravenous glucose infusion

Intervention type: OTHER
Intervention: Isoglycemic intravenous glucose infusion

Intervention type: OTHER
Intervention: Isoglycemic intravenous glucose infusion

Intervention type: OTHER
Intervention: Isoglycemic intravenous glucose infusion
Study: NCT02726607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Infant Tracking System (HITSystem) 2.0
Description: The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of PMTCT care
Description: Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
Study: NCT04469556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/nab-paclitaxel
Description: Chemotherapy
Study: NCT02080494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT03990051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-ocular™ topical gel
Description: Topical gel for forehead dermal application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical gel
Description: Topical gel for forehead dermal application
Study: NCT01601873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPATEN
Description: Heparin-bonded graft implantation for hemodialysis vascular access
Study: NCT00510120

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT02041065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterjet induced dissection
Description: Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CUSA induced dissection
Description: Ultrasound based destruction of the liver
Study: NCT02343783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergic Skin Reaction (ASR) Testing and Skin Blister Induction
Description: Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
Study: NCT00933257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration 5 weeks
Study: NCT05386940

Intervention type: OTHER
Intervention: PKN1 level
Description: different PKN1 level after on-pump cardiac surgery

Intervention type: OTHER
Intervention: PKN1 level
Description: different PKN1 level after on-pump cardiac surgery

Intervention type: OTHER
Intervention: PKN1 level
Description: different PKN1 level after on-pump cardiac surgery
Study: NCT01162707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF Pressure Measurement System
Description: Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
Study: NCT02176785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
Study: NCT02581397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transpulmin suppository
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaiacol suppository
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transpulmin syrup
Description: 7,5ml every 4 hours, orally, for 03 or 07 days
Study: NCT03987321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrarenal vena cava filter placement
Description: Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrarenal vena cava filter placement
Description: Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
Study: NCT00564733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT03920592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality of Bullying
Description: Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings
Study: NCT03922776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment
Study: NCT03671616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
Study: NCT03581409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin protect tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin protect tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol tablet
Study: NCT00328692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofyline Pbo 30 mg IV QD; 3 days
Study: NCT02977897

Intervention type: DRUG
Intervention: Octreotide Acetate
Description: Octreotide 100mcg SC q12h for 5 days
Study: NCT05521659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol
Description: Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
Study: NCT02492659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser-assisted cataract surgery
Description: the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional phacoemulsification
Description: continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
Study: NCT04410237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-Jet
Description: One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Syringe
Description: One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score
Study: NCT03195335

Intervention type: OTHER
Intervention: Assessment via questionnaire
Description: All the children will be assessed via assessment questionnaires.
Study: NCT00160069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 16 mg/m2, 3-hour infusion, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 30-min infusion, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 3-hour infusion, every 3 weeks
Study: NCT01143766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard sedation regimen
Description: Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
Study: NCT00338455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
Description: 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Standard Care+dobutamine or milrinone
Description: 28-day continuous infusion, no bolus
Study: NCT04190108

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin assay
Description: FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin assay
Description: FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
Study: NCT01601873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Graft
Description: non-heparin bonded conventional hemodialysis vascular access graft
Study: NCT00138554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study: NCT01172990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Invasive Management
Description: Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Management
Description: Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
Study: NCT04330040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet
Study: NCT01018615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silymarin
Description: capsules, 700 mg, twice daily, 12 days
Study: NCT00564733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT01018615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silymarin
Description: capsules, 700 mg, twice daily, 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract (EGCG)
Description: capsules, 196.5 mg, twice daily, 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract (EGCG)
Description: capsules, 196.5 mg, twice daily, 12 days
Study: NCT04844567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Synch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Synch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Asynch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Asynch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration.
Study: NCT02159001

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electroconvulsive therapy
Description: 10-course, three times a week bilateral frontotemporal ECT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: 10-course, three times a week bilateral frontotemporal ECT
Study: NCT03309241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Single Ascending Doses of PF-06882961 from 3mg to TBD mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Single Ascending Doses of PF-06882961 from 3mg to TBD mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Single Ascending Doses of PF-06882961 from 3mg to TBD mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Single Dose